Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Decreases By 11.1%

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 16,800 shares, a decline of 11.1% from the January 15th total of 18,900 shares. Based on an average trading volume of 6,200 shares, the days-to-cover ratio is presently 2.7 days.

Jasper Therapeutics Price Performance

NASDAQ JSPRW traded down $0.01 on Monday, hitting $0.15. The company had a trading volume of 1,348 shares, compared to its average volume of 11,862. The company’s fifty day moving average price is $0.18 and its 200-day moving average price is $0.20. Jasper Therapeutics has a 12-month low of $0.09 and a 12-month high of $0.27.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.